Gene Analysis

基因分析共享资源（GASR）为马约诊所癌症中心的研究人员提供了高效， 高质量，具有成本效益的获得最先进的基因组学技术，用于研究基因结构， 功能自2003年以来，全球安全战略各组成部分一直以协调一致的方式开展工作， DMA测序、基因表达、基因测序、基因 分析和基因分型。2007年，通过RNAi分析支持基因表达调控。 该设施提供的服务包括使用ABI 3730x1的大规模全方位重测序分析 测序仪，加上全面的基因分型和基因转录本分析使用AffysseGenechip？ 技术和Illumina BeadChips。我们最近增加的功能包括Agilent阵列CGH和 在Illumina 1G基因组分析仪上进行miRNA分析以及NextGen测序 竞争性赠款更新，130多名癌症中心成员使用了由 GASR和癌症中心项目占GASR所有活动的三分之二左右。 GASR的主要目标是为马约研究人员带来尖端的基因组技术， 这样做在一个负担得起的价格。这包括但不限于：i.保持坚实的专业知识， 用于基因组分析并将这些知识转化为高质量数据的明确商业平台 对于癌症中心成员，ii.继续探索、验证和实施新技术 这将提高GASR提供尖端基因组测定的能力，iii.加强 通过开发方法学，利用存档的和新鲜的临床样本， 福尔马林固定、石蜡包埋（FFPE）和激光捕获显微切割的少量核糖核酸 组织，iv.探索新技术，如“下一代测序”和miRNA 根据GASR用户的意见进行分析，以持续改进。此外，我们将继续 与生物信息学和生物统计学密切合作，确保对生成的数据进行无缝解释 通过GASR服务。

The Gene Analysis Shared Resource (GASR) provides Mayo Clinic Cancer Center researchers efficient, high-quality, cost-effective access to state-of-the-art genomics technologies for studying gene structure and function. Since 2003, the GASR components have been working in a coordinated fashion to provide technical expertise, instrumentation, and coordinated support for DMA sequencing, gene expression profiling, and genotyping. Support for gene expression regulation through RNAi analysis was added in 2007. The services provided by the facility include large-scale, full-service re-sequencing analysis using ABI 3730x1 sequencers, plus comprehensive genotyping and gene transcript analysis using Affymetrix Genechip¿ technology and Illumina BeadChips. Recent additions to our capabilities include Agilent array CGH and miRNA analysis as well as NextGen sequencing on an Illumina 1G Genome Analyzer Since the last competitive grant renewal, more than 130 Cancer Center members have used the services offered by the GASR and Cancer Center projects account for about two-thirds of all the activity in the GASR. The primary goals of the GASR are to bring cutting edge genomic technologies to Mayo researchers and to do so at an affordable price. This includes, but is not limited to: i. maintaining solid expertise in the use of well-defined commercial platforms for genomic analysis and translating this knowledge into high quality data for Cancer Center members, ii. continued exploration, validation, and implementation of new technologies which will advance the capabilities of the GASR to provide cutting edge genomic assays, iii. enhancement of the utility of archived and fresh clinical samples by developing methodologies which allow for the use of very small amounts of ribonucleic acid from formalin fixed, paraffin embedded (FFPE) and laser-captured microdissected tissues, iv. exploration of new technologies, such as "next generation sequencing," and miRNA profiling based on input from users of the GASR for continuous improvement. In addition, we will continue to work closely with bioinformatics and biostatistics to insure seamless interpretation of the data generated through GASR services.